COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

CPTAC Genomic Data Now Available in the NCI Genomic Data Commons (GDC)

CPTAC GDCCPTAC is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of robust, quantitative, proteomic technologies and workflows. The overarching goal of CPTAC is to improve our ability to diagnose, treat and prevent cancer. To achieve this goal in a scientifically rigorous manner, the NCI launched CPTAC to systematically identify proteins that derive from alterations in cancer genomes and related biological processes, and provide this data with accompanying assays and protocols to the public.

CPTAC has provided the Genomic Data Commons (GDC) with genomic data from a total of 300+ cancer patients with diverse disease types including Uterine Corpus Endometrial Carcinoma (UCEC), Clear Cell Renal Cell Carcinoma (CCRCC), and Lung Adenocarcinoma (LUAD). The GDC harmonized DNA sequences from CPTAC whole genome sequencing (WGS) and whole exomes sequencing (WXS) with the GRCh38 reference genome using GDC DNA-Seq Analysis Pipelines. The CPTAC harmonized genomic data is available in the GDC Data Portal. CPTAC makes proteomic data that are processed through the CPTAC Common Data analysis Pipeline (CDAP) available in the CPTAC Data Portal.